Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

WageWorks’ Growth Stems from Acquisitions Rather Than New Clients (WAGE)

Research Question: Will WageWorks’ organic growth continue at its projected pace of 9% to 14%? Companies: BNFT, CNDT, HQY, MMC, TNET, UMBF, WAGE, WLTW By: Reverdy Johnson Click here to download report (.pdf)   Summary of Findings WageWorks Inc. (WAGE) is more likely to see its growth come from acquisitions rather than organically. Seven of […]

Read more...

XRAY’s New Distribution Will Increase Sales and Adoption of Digital Dentistry (XRAY)

Research Question: Will Dentsply Sirona’s new North American distribution agreements accelerate digital dentistry adoption and reverse the company’s recent sales decline? Companies: ALGN, HSIC, IART, MMM, PDCO, SWX:NOBN, SWX:STMN, XRAY, ZBH By: David Franklin Click here to download report (.pdf)   Summary of Findings Dentsply Sirona Inc.’s (XRAY) new distribution agreements with Henry Schein Inc. […]

Read more...

Wageworks Idea Proposal (WAGE)

Wageworks Idea Proposal (WAGE)

Will Wageworks’ organic growth continue at its projected pace of 9% to 14%?   Report Available:October 25, 2017   Blueshift’s initial research found a trend toward high-deductible health plans and growth in the consumer-directed benefits market. WAGE is the leader in this space and enters the enterprise selling season with solid growth in RFPs, while […]

Read more...

Dentsply Sirona Idea Proposal (XRAY)

Dentsply Sirona Idea Proposal (XRAY)

Will Dentsply Sirona’s new U.S. and Canadian distribution agreements accelerate digital dentistry adoption and reverse its recent sales decline?   Report Available: October 11, 2017   Blueshift’s initial research found XRAY’s sales in decline as dentists wait on purchasing high margin equipment until after the new expanded distribution program starts September 1. XRAY anticipates that […]

Read more...

Nevro’s Senza Offers Unique Treatment Option; Adoption and Sales Will Be Steady (NVRO)

Research Question: Is Nevro’s Senza spinal cord stimulation system the best nondrug chronic pain solution? Companies: ABT, BSX, MDT, NVRO, NVTR By: David Franklin Click here to download report (.pdf)   Summary of Findings Nevro Corp.’s (NVRO) Senza system is providing physicians and patients with chronic lower back and leg pain with a unique HF10 […]

Read more...

Nevro Idea Proposal (NVRO)

Nevro Idea Proposal (NVRO)

Is Nevro’s Senza spinal cord stimulation system the best non-drug chronic pain solution? Report Available: July 26, 2017   Blueshift’s initial research found NVRO aggressively and successfully ramping up sales of its Senza system. The Senza system has energized the 30-year-old spinal cord stimulation industry with its innovative HF10 high frequency therapy. As the opioid […]

Read more...

Healthcare Reform Uncertainty, Hospital Innovation Slow Demand For Temp/Travel Nurses (AMN, CCRN)

Research Question: Has the nursing shortage peaked? How will the leading providers of temporary nurses be affected by the current nursing staffing cycle? Companies: AMN, CCRN By: David Franklin Click here to download report (.pdf)   Summary of Findings The nursing shortage has not yet peaked, according to 12 of 18 sources who said the […]

Read more...

Nursing Staffing Idea Proposal (AMN, CCRN)

Nursing Staffing Idea Proposal (AMN, CCRN)

Has the nursing shortage peaked? How will the leading providers of temporary nurses be affected by the current nursing staffing cycle?   Report Available:June 14, 2017   Blueshift’s initial research found that the existence of a nurse shortage and its future is a frequently discussed, debated and studied issue. U.S. government agencies have researched the situation […]

Read more...

Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market (INDV)

Research Question: How will the new long-acting buprenorphine options and changing government rules affect the opioid abuse treatment market? Companies: ALKS, DEPO, LON:INDV, STO:CAMX, STO:ORX, TTNP By: David Franklin Click here to download report (.pdf)   Summary of Findings Weekly and monthly injectable buprenorphine treatments that could significantly affect the medication-assisted treatment (MAT) market for […]

Read more...

Buprenorphine Idea Proposal (INDV)

Buprenorphine Idea Proposal (INDV)

How will the new long-acting buprenorphine treatment option and changing government rules affect the opioid treatment market? Report Available:March 2, 2017   Blueshift’s initial research found the opioid dependence treatment market on the verge of a major disruption. Due to the opioid addiction epidemic, government rules and regulations are allowing physicians to expand the number […]

Read more...